Further analysis of brain tumors by immunohistochemistry (IHC) revealed the presence of P-FAK in vehicle or avutometinib cohorts and reduced P-FAK in those treated with VS-4718 alone or in combination with avutometinib. Here, PTK2 is linked to brain neoplasm.